Interpretation of the BIO Protocol ecosystem: 7 sub-DAOs, 2 MEMEs

avatar
ChainCatcher
a day ago
This article is machine translated
Show original

Author: TechFlow

On December 23, Binance announced the launch of its 63rd Launchpool project, Bio Protocol (BIO).

What is Bio Protocol?

BIO Protocol is a decentralized science (DeSci) curation and liquidity protocol, first invested in by Binance Labs, aimed at providing support and resources for scientific research projects to promote innovation in scientific research.

You can understand it as the "on-chain version of Y Combinator for science".

BIO Protocol includes core components such as BioDAO, curation system, IP-ization and liquidity, and incentive mechanisms. Through multiple rounds of auctions and airdrop programs, it has built a diverse and highly engaged community, laying the foundation for a decentralized biomedical research network.

The most important component is BioDAO, which raises funds through token sales and uses its funds to support and develop biotech projects related to its mission, creating shared intellectual property ownership among its members.

According to the official website, 7 sub-DAOs have been successfully launched so far, 3 sub-DAOs are still ongoing, with a total of $23.5 million raised and $7.2 million in research funds deployed.

The 7 sub-DAOs that have been launched:

- $VITA (VitaDAO): A group focused on funding early-stage longevity research, which has received investment from Pfizer, and during Devcon, VitaDAO also showcased its first longevity product VD001, a high-dose spermidine supplement approved by the Thai FDA.

It is worth noting that BIO Protocol co-founder Paul Kohlhaas is also the founder of VitaDAO and the author of the VitaDAO whitepaper.

- $ATH (AthenaDAO): Focused on women's reproductive health research and drug discovery

- $GROW(ValleyDAO): A decentralized, community-governed platform for anti-aging drugs and longevity projects

-$PSY (PsyDAO): Focused on psychedelic science research, has completed its first PSY token sale in mid-November 2024, raising $2 million.

—HAIR (HairDAO): Aimed at solving hair loss issues, has launched the Follicool shampoo product without harmful parabens or sulfates. Consumers receive 1 million POO tokens for each bottle of FolliCool ($49.95) purchased.

-CRYO (CryoDAO): Dedicated to advancing cryopreservation research.

-$NEURON (CerebrumDAO): Promoting brain health, has raised over $1.5 million.

pump.science: A DeSci funding platform sponsored by the Solana Foundation

In September this year, the Solana Foundation provided a grant to the company of BIO Protocol co-founder, Molecule, to build a DeSci funding platform based on Solana, called pump.science, built on top of Pump.fun.

Let me restate this content more clearly in Chinese:

Currently, two experimental studies are underway on the pump.science platform:

  1. Rifampicin (RIF)

  2. Urolithin A (URO)

Both of these experiments are currently in the fruit fly testing stage.

About these two compounds:

  • RIF is an important antibiotic, mainly used to treat bacterial infections such as tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease. Research has found that it can activate the natural defense mechanisms of cells in organisms like the nematode Caenorhabditis elegans, helping them resist stress and damage.

URO is a compound produced by the human body when digesting foods containing tannins, such as pomegranates. Its main function is to promote mitophagy, i.e., the clearance of aged and dysfunctional mitochondria, providing space for new healthy mitochondria to grow. Human research data shows that this substance has promising potential in improving muscle health and boosting energy levels.

Other important DeSci assets:

- $RSC (ResearchHub): Founded by Coinbase co-founder, used to reward users for publishing high-quality content on the platform.

-$DRUGS, the a16z of the DeSci field, manages a portfolio of DeSci tokens, a crypto-native biotech fund.

Source
Disclaimer: The content above is only the author's opinion which does not represent any position of Followin, and is not intended as, and shall not be understood or construed as, investment advice from Followin.
Like
Add to Favorites
Comments